BioSpace News Archive

Exclusive Aplio i-series Technology Enables up to 50cm Depth

Technavio analysts forecast the global ricinoleic acid market to grow at a CAGR of nearly 5% during the forecast period, according to their latest market research report.

PRIVIT’s platform provides a solution that allows team officials to properly oversee compliance, monitor special medical conditions, distribute educational health videos, and securely store participant information for an organization.

In total, 11,222,349 units of Australis were sold in the public markets.

The National Pharmaceutical Council (NPC) today announced that Richard H. Bagger, Executive Vice President, Corporate Affairs and Market Access, Celgene Corporation, has been elected Chair of NPC’s Board of Directors for 2018-2019.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that nine abstracts, including two oral presentations, relating to the company’s hematology/oncology portfolio were accepted for the 60th American Society of Hematology (ASH) Annual Meeting in San Diego from December 1-4.

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12th at 1:20 p.m. ET in New York, NY.

Dr. Reddy’s Laboratories Ltd. today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

Cryoablation shows early indications of effectiveness in treating women with low-risk breast cancers, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA).

DexCom, Inc. announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended